pharmaceuticals-and-healthcare

Global Onychomycosis (Tinea Unguium) Drug Sales Market Report 2017


Published On : Mar 2017

Category : Pharmaceutical

No. of Pages : 142 pages

  • $4000
  • $8000

Please click below to avail discount on this report

This report studies the Onychomycosis (Tinea Unguium) Drug market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Onychomycosis (Tinea Unguium) Drug market by product type and applications/end industries.

In the last several years, global market of Onychomycosis (Tinea Unguium) Drug change huge. In 2016, global revenue of Onychomycosis (Tinea Unguium) Drug is nearly 2591.81 M USD. And the global growth rate is at 5.11% from 2012 to 2016.


The major players in global market include
Johnson & Johnson
GSK
Novartis
Pfizer
Valeant Pharma
Kaken Pharmaceutical
Galderma
Xiuzheng Pharmaceutical
Letai
Qilu Pharmaceutical

Geographically, this report is segmented into several key regions, with revenue, market share (%) and growth Rate (%) of Onychomycosis (Tinea Unguium) Drug in these regions, from 2012 to 2022 (forecast), covering
USA
China
Europe
Japan



On the basis of product, the Onychomycosis (Tinea Unguium) Drug market is primarily split into
Oral
External

On the basis on the end users/applications, this report covers
Age under 18
Age 18-50
Age above 50


In the recent times, the global market for Global onychomycosis tinea unguium drug sales market report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of Global onychomycosis tinea unguium drug sales market report 2017 across the world. Manufacturers have turned to technological innovations and data-driven customization to satisfy the augmenting consumer demand for efficiency and more accuracy in results, leading to an increased usage of technology in the Global onychomycosis tinea unguium drug sales market report 2017 production processes, which is also reflecting positively on the growth of this market.

The research report on the Global onychomycosis tinea unguium drug sales market report 2017 is an analytical study which comprehensively analyzes the competitive framework of this market. Using a number of effective assessment tools, such as porter’s five forces and value chain analysis, it performs in-depth analyses of the production and supply as well as the demand and sales of Global onychomycosis tinea unguium drug sales market report 2017 and provides deep insights into the future prospects of this market.

The study begins with a detailed overview of the market for Global onychomycosis tinea unguium drug sales market report 2017, including the definition, classification, and industry chain structure of Global onychomycosis tinea unguium drug sales market report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. Focusing specifically on the key trends, it further evaluates the overall performance of this market during the assessment period. With chemical industry undergoing a phase of technological disruption, innovations in products are likely to shape the future of the Global onychomycosis tinea unguium drug sales market report 2017.

In this research report, apart from the trends, the driving forces, restraints, and opportunities have also been taken into consideration to determine the market’s future. Further, it offers an estimation of the market size in terms of value (US$) and in volume (kilo tons) and talks about the key segments and the geographical subdivisions of the market for Global onychomycosis tinea unguium drug sales market report 2017 in details. It provides in-depth information on the development trends and the policies and regulations, concerning Global onychomycosis tinea unguium drug sales market report 2017, implemented in each of the geographical segments. The predominant applications of the Global onychomycosis tinea unguium drug sales market report 2017 have also been discussed at length in this research study.

With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for Global onychomycosis tinea unguium drug sales market report 2017 at present and are projected to remain doing so over the forecast period. Readers will also benefit significantly from the important information regarding this market, provided in the forms of figures and tables in the research report.

Additionally, the information on the latest developments in this market, both, at the global as well as regional level, is expected to enhance the decision-making capability of the reader. Up-to-date information on various specifications, buyer analysis, their purchasing volume, prices, and price analysis, and deep insights on the leading suppliers have also been provided in this study for the readers.

At last, the report offers key industry recommendations to companies looking to venture into the Global onychomycosis tinea unguium drug sales market report 2017 from both the perspectives, i.e. demand and supply. The main objective of this research study is to assist stakeholders operating in this market in creating efficient counter strategies to gain an edge over their competitors.

List of Tables and Figures

Figure Product Picture of Onychomycosis (Tinea Unguium) Drug1
Table Global Onychomycosis (Tinea Unguium) Drug by Types2
Figure Global Onychomycosis (Tinea Unguium) Drug Sales Market Share (%) by Types in 20162
Figure Oral Product Picture3
Figure External Product Picture3
Table Global Onychomycosis (Tinea Unguium) Drug Market by Applications/End Users4
Figure Global Sales Market Share (%) of Onychomycosis (Tinea Unguium) Drug by Applications in 20164
Figure Age under 18 Examples5
Figure Age 18-50 Examples5
Figure Age above 50Examples6
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2022)7
Figure China Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2022)8
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2022)9
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2022)10
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2022)11
Table Global Onychomycosis (Tinea Unguium) Drug Revenue by Players (2012-2017)12
Table Global Onychomycosis (Tinea Unguium) Drug Revenue Share (%) by Players (2012-2017)12
Figure 2016 Global Onychomycosis (Tinea Unguium) Drug Revenue Share (%) by Players13
Figure 2017 Global Onychomycosis (Tinea Unguium) Drug Revenue Share (%) by Players14
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Market Share (%) by Type (2012-2017)14
Table Global Onychomycosis (Tinea Unguium) Drug Sales Share (%) by Type (2012-2017)15
Figure Market Share (%) of Onychomycosis (Tinea Unguium) Drug by Type (2012-2017)15
Figure Global Onychomycosis (Tinea Unguium) Drug Market Share (%) by Type in 201616
Figure Global Onychomycosis (Tinea Unguium) Drug Market Share (%) by Type in 201716
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Market Share (%) by Regions (2012-2017)17
Table Global Onychomycosis (Tinea Unguium) Drug Revenue Share (%) by Regions (2012-2017)17
Figure Revenue Market Share (%) of Onychomycosis (Tinea Unguium) Drug by Regions (2012-2017)18
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Regions in 201619
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Regions in 201720
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Market Share (%) by Application (2012-2017)20
Table Global Onychomycosis (Tinea Unguium) Drug Revenue Share (%) by Application (2012-2017)20
Figure Revenue Market Share (%) of Onychomycosis (Tinea Unguium) Drug by Application (2012-2017)21
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Growth Rate by Application (2012-2017)22
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate (2012-2017)23
Table USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Players (2012-2017)23
Table USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Players (2012-2017)24
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201624
Table USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Type (2012-2017)25
Table USA Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type (2012-2017)25
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Type in 201625
Table USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Applications (2012-2017)26
Table USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Applications (2012-2017)26
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201627
Figure China Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate (2012-2017)28
Table China Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Players (2012-2017)28
Table China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players (2012-2017)29
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201629
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201730
Table China Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Type (2012-2017)30
Table China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type (2012-2017)30
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201631
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201731
Table China Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Applications (2012-2017)32
Table China Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Applications (2012-2017)32
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201632
Figure China Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201733
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate (2012-2017)34
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD) by Players (2012-2017)35
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players (2012-2017)35
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201636
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201736
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Type (2012-2017)37
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Type (2012-2017)37
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201637
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201738
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Applications (2012-2017)38
Table Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications (2012-2017)38
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201639
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201740
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate (2012-2017)41
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Players (2012-2017)41
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players (2012-2017)42
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Players in 201642
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD)Market Share (%) by Players in 201743
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Type (2012-2017)43
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type (2012-2017)43
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201644
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Type in 201744
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD)by Applications (2012-2017)45
Table Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications (2012-2017)45
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201645
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) by Applications in 201746
Table Johnson & Johnson Company Profile47
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Johnson & Johnson48
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin 2012-201748
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Johnson & Johnson 2012-201749
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Johnson & Johnson 2012-201749
Table GSK Company Profile50
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of GSK51
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of GSK 2012-201751
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of GSK 2012-201752
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of GSK 2012-201752
Table Novartis Company Profile53
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Novartis54
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Novartis 2012-201754
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Novartis 2012-201755
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Novartis 2012-201755
Table Pfizer Company Profile56
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Pfizer57
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Pfizer 2012-201757
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Pfizer 2012-201758
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Pfizer 2012-201758
Table Valeant Pharma Company Profile59
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Valeant Pharma60
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Valeant Pharma 2012-201760
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Valeant Pharma 2012-201761
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Valeant Pharma 2012-201761
Table Kaken Pharmaceutical Company Profile62
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Kaken Pharmaceutical63
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Kaken Pharmaceutical 2012-201763
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Kaken Pharmaceutical 2012-201764
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Kaken Pharmaceutical 2012-201764
Table Galderma Company Profile65
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Galderma66
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Galderma 2012-201766
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Galderma 2012-201767
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Galderma 2012-201767
Table Xiuzheng Pharmaceutical Company Profile68
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Xiuzheng Pharmaceutical69
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Xiuzheng Pharmaceutical 2012-201770
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Xiuzheng Pharmaceutical 2012-201770
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Xiuzheng Pharmaceutical 2012-201771
Table Letai Company Profile71
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Letai72
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Letai 2012-201772
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Letai 2012-201773
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Letai 2012-201773
Table Qilu Pharmaceutical Company Profile74
Figure Onychomycosis (Tinea Unguium) Drug Product Introduction of Qilu Pharmaceutical75
Table Onychomycosis (Tinea Unguium) Drug Revenue (M USD), Cost (M USD), Gross (M USD), and Gross Margin of Qilu Pharmaceutical 2012-201775
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate of Qilu Pharmaceutical 2012-201776
Figure Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Global Market Share of Qilu Pharmaceutical 2012-201776
Figure typical phases from research to the market for a drug candidate78
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound79
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound79
Figure Manufacturing Cost Structure of Onychomycosis (Tinea Unguium) Drug80
Figure Assessment of API Manufacturing Cost By Region81
Figure 2016 Manufacturing Labor Cost Per Hour in China as a Proportion of Those in Other Countries (%)82
Figure Manufacturing Labor Costs in Select Provinces and Countries in 201682
Figure 2016 Global Manufacturing Competitiveness Index rankings by country83
Figure US Nonfarm Unit Labor Cost 2014-201684
Figure United States Average Hourly Wages (USD/H) 2016-201784
Figure China Labor Cost Index 2014-201685
Figure China Average Yearly Wages 2006-201685
Figure Euro Area Labor Cost 2014-201686
Figure Japan Overview of Average Monthly Wages 2012-2017(JPY Thousand/Month)86
Figure Manufacturing Process Analysis of Onychomycosis (Tinea Unguium) Drug87
Figure Onychomycosis (Tinea Unguium) Drug Industrial Chain Analysis88
Table Major Buyers of Onychomycosis (Tinea Unguium) Drug89
Figure Marketing Channel for Onychomycosis (Tinea Unguium) Drug91
Figure Onychomycosis (Tinea Unguium) Drug Marketing Channel92
Table Distributors/Traders List96
Table Albaconazole Phase II trial outcomes99
Table Posaconazole Phase II trial outcomes99
Table Efinaconazole Phase II trial outcomes100
Table Efinaconazole Phase III trial outcomes100
Figure Global GDP Growth Rate for 2015101
Figure US GDP 2006-2016 (Billion USD)102
Figure US CPI Change 2016-2017102
Figure EU GDP 2006-2016 (Billion USD)103
Figure EU CPI Change 2012-2016103
Figure Germany GDP 2006-2016 (Billion USD)104
Figure Germany CPI Change 2016-2017104
Figure UK GDP 2006-2016 (Billion USD)104
Figure UK CPI Change 2016-2017105
Figure Italy GDP 2006-2016 (Billion USD)105
Figure Italy CPI Change 2016-2017106
Figure Japan GDP 2006-2016 (Billion USD)106
Figure Japan CPI Change 2012-2016107
Figure China GDP 2006-2016 (Billion USD)107
Figure China CPI Change 2016-2017108
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate Forecast (2017-2022)109
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) Forecast by Regions (2017-2022)110
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Regions (2017-2022)110
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Regions in 2022111
Figure USA Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate (%) Forecast (2017-2022)112
Figure Europe Onychomycosis (Tinea Unguium) Drug Revenue (M USD)and Growth Rate (%) Forecast (2017-2022)113
Figure China Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate Forecast (2017-2022)114
Figure Japan Onychomycosis (Tinea Unguium) Drug Revenue (M USD) and Growth Rate Forecast (2017-2022)115
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) Forecast by Type (2017-2022)115
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Type (2017-2022)116
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Type in 2022116
Table Global Onychomycosis (Tinea Unguium) Drug Revenue (M USD) Forecast by Application (2017-2022)117
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Application (2017-2022)117
Figure Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share (%) Forecast by Application in 2022118
Table Research Programs/Design for This Report121
Figure Bottom-up and Top-down Approaches for This Report123
Figure Data Triangulation124
Table Key Data Information from Secondary Sources125
Table Key Data Information from Primary Sources126

Send an Enquiry

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top